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The AHR is well known for regulating responses to an array of environmental chemicals.  
A growing body of evidence supports the hypothesis that the AHR also plays perhaps an even 
more important role in modulating critical aspects of cell function including cell growth, death, 
and migration. As these and other important AHR activities continue to be elucidated, it becomes 
apparent that attention now must be directed towards the mechanisms through which the AHR 
itself is regulated. Here, we review what is known of and what biological outcomes have been 
attributed to the AHR repressor (AHRR), an evolutionarily conserved bHLH-PAS protein that 
inhibits both xenobiotic-induced and constitutively active AHR transcriptional activity in 
multiple species. We discuss the structure and evolution of the AHRR and the dominant 
paradigm of a xenobiotic-inducible negative feedback loop comprised of AHR-mediated 
transcriptional up-regulation of AHRR and the subsequent AHRR-mediated suppression of AHR 
activity. We highlight the role of the AHRR in limiting AHR activity in the absence of 
xenobiotic AHR ligands and the important contribution of constitutively repressive AHRR to 
cancer biology. In this context, we also suggest a new hypothesis proposing that, under some 
circumstances, constitutively active AHR may repress AHRR transcription, resulting in unbridled 
AHR activity. We also review the predominant hypotheses on the molecular mechanisms 
through which AHRR inhibits AHR as well as novel mechanisms through which the AHRR may 
exert AHR-independent effects. Collectively, this discussion emphasizes the importance of this 
understudied bHLH-PAS protein in tissue development, normal cell biology, xenobiotic 




































































Historically, the AHR has been studied for its transcriptional regulation of genes 
encoding cytochrome P450 enzymes that metabolize environmental AHR ligands, sometimes 
producing mutagenic and toxic intermediates. Given this focus, it is not surprising that the 
outcomes of AHR activation most frequently studied have been malignant transformation and 
cell toxicity. However, the highly conserved structure of the AHR and its expression in 
embryonic as well as adult organs as disparate as the liver, lung, lymphatics, and brain hint at the 
possibility that the AHR plays other, potentially more important physiologic roles in the absence 
of xenobiotic ligands. Indeed, recent studies demonstrated a myriad of biologic activities 
ascribed to AHR activated in the absence of exogenous ligands, ranging from control of 
mammary tumorigenesis [1-6] to regulation of autoimmunity [7-9]. That other members of the 
PAS family are associated with critical biologic functions such as regulation of neurologic 
development and the circadian cycle, responses to hypoxia, and angiogenesis [10, 11] is
consistent with the hypothesis that PAS proteins in general evolved to regulate important 
biologic processes. In this context, several studies summarized here and in accompanying articles 
in this issue of Biochemical Pharmacology now demonstrate a wide range of AHR-regulated 
cellular activities. What is not completely understood is how these AHR-mediated activities are 
controlled. Nevertheless, negative regulation by transcriptional repressors is an important feature 
of other PAS proteins involved in critical signaling functions; examples include the negative 
regulation of HIF by iPAS [12] and of Sim1 and NXF by Sim2 [13, 14]. Similarly, a 
compendium of transcriptional co-activators and co-repressors that physically associate with and 



































































Herein we extend these discussions to consider an important but poorly understood 
regulator of the AHR, the AHR repressor (AHRR). Many studies now show that the AHRR 
plays a critical role in modulating “normal” as well as xenobiotic-induced AHR transcriptional 
activity. To highlight the significance of both temporal (developmental) and spatial (cell and 
tissue-specific) regulation of AHR signaling by the AHRR, we begin with a brief summary of 
some of the important, physiologically relevant activities of the AHR and note how AHRR might 
be involved in their regulation. 
2. Controlling the AHR, an important physiological process
A large body of work demonstrates that the AHR contributes to regulation of cell growth 
[1, 2, 18-34]. For example, there is an association between increased AHR expression or activity 
and fibroblast, lymphocyte, hepatocyte, and mammary tumor growth [1, 2, 18-22]. AHR-
deficient hepatoma cells grow more slowly than wildtype cells, and transfection of AHR cDNA 
into the mutant cells increases their growth rate to that of wildtype cells [25]. Progression of 
murine or human hepatoma cells from G1 to S is prolonged by transfection of AHR antisense 
cDNA or inhibitory siRNA [25, 26]. AHR siRNA-mediated growth inhibition is accompanied by 
down-regulation of cyclin D1, cyclin E, cdk2, and cdk4 [26]. Expression in HeLa cells of 
BRCA1, an important regulator of cell growth and DNA integrity [35], requires binding of the 
constitutively active AHR [36] to the BRCA1 promoter [37]. Possible pathways for AHR
agonist-induced growth regulation include altered TGF- signaling [38], induction of p27Kip1 [33, 
39], AHR-Rb interaction [34, 40], and AHR displacement of p300 on the E2F promoter [39, 41]. 
In estrogen receptor-(ER) positive mammary tumors, AHR activation with exogenous 
ligands induces AHR-ER interaction [42, 43], ER degradation [44, 45], suppression of ER



































































to the growth of mammary tumors, particularly early in the transformation process, these AHR-
ER signaling pathway interactions suggest an obvious mechanism for AHR-mediated growth 
inhibition, at least in some tumor subsets. Interestingly, the ability of AHR activation to decrease 
estrogen-induced hsp27 [48] and BRCA1 [49] transcription suggest mechanisms through which 
the AHR may actually increase growth and/or survival in ER+ cells. Studies evaluating AHRR 
activity during the cell cycle might reveal that the equilibrium between AHR and AHRR activity, 
rather than just the level of AHR expression, is the critical measure of AHR contribution to cell 
growth. 
Regulation of apoptosis represents a second critical area in which the AHR appears to 
play an important role [41, 50-52, 53, 54] and for which AHRR regulation of the AHR has not 
yet been evaluated. The AHR provides a survival advantage to murine hepatoma cells in which 
the intrinsic apoptosis pathway is initiated by UV irradiation [50]. In contrast, the AHR is 
required for optimal TNF--plus-cytoxan-induced apoptosis through a lysosomal-dependent 
process [53] and for Fas-mediated apoptosis [54]. Furthermore, constitutively active or PAH-
induced AHR induces apoptosis in murine and human oocytes through AHRE binding and 
transactivation of Bax [51, 52]. This latter observation points to an extremely critical AHR 
function, regulation of fetal or neonatal oocyte atresia and thereby female fertility. Recent 
evidence linking AHRR to reproductive disorders (see below) and the control of apoptosis [55]
suggest a possible role for AHRR in regulating mammalian reproduction.
Similarly, there now exists evidence for a role for the AHR in migration of normal and 
malignantly transformed cells (reviewed in [4]). For example, there is an acute increase in human 
mammary tumor cell invasiveness within 24 hours of B[a]P treatment and AHR inhibitors block 



































































exhibit a decrease in migration in vitro and in vivo, lamellipodia formation, and VEGF receptor 
expression in vitro, all of which have been implicated in cell motility and/or invasiveness [57]. 
At least part of this influence on migration or invasion may be mediated by AHR transcriptional 
control of Slug [6, 58, 59], a master regulator of epithelial to mesenchymal transition, or CK2, a 
serine/threonine kinase that regulates Snail, a second critical regulator of cell invasion. Both Slug
and CK2 promoters contain multiple AHREs. The ability of the AHRR to control these or other 
AHR-mediated activities in tumor models has only begun to be studied [55, 60], although early 
results indicate that the AHRR can down-regulate AHR activity and Slug protein expression in 
murine mammary tumor cells [6].
Another important physiological role of AHR is in vascular development. In AHR-/- or 
AHR-hypomorphic mice, the ductus venosus fails to close after birth, resulting in persistent 
shunting of portal blood flow [61]. Additional studies show that this effect on vascular 
development involves AHR expressed in vascular endothelial cells [62]. The vascular defects in 
AHR-hypomorphic mice can be rescued by treatment with AHR agonists [63], implying that 
endogenous activation of the AHR is involved in vascular development.  Whether AHRR may 
have a role in regulating the AHR during vascular development has not been investigated.
It is increasingly appreciated that the AHR plays an important role during immune 
responses. For example, activation of human B cells with stimuli that mimic signals delivered to 
B cells either during an innate or adaptive immune response, i.e, CpGs or CD40 ligand 
respectively, up-regulates AHR expression and results in constitutive AHR activation [18]. 
Constitutively active AHR in these activated B cells likely regulates cell growth, as demonstrated 
by the modest but statistically significant decrease in B cell growth following AHR down-



































































repress AHR activity in the immune system has not been examined. For example, the ability of 
constitutively active AHR to up-regulate AHRR expression in a feedback loop and the ability of 
AHRR, presumably expressed in these cells, to limit AHR-regulated cell growth is unknown. A 
similar situation exists in what is a rapidly growing area of study, defining the role of the AHR in 
development of regulatory (Treg) and IL-17-secreting (Th17) T cells. These T cell subsets play 
critical roles in autoimmunity, graft rejection, and tumor immunity. While several very recent 
studies implicate the AHR in development and/or function of these important T cell subsets [7-9, 
64, 65], none have evaluated AHRR control of AHR activity in the immune system during 
autoimmune or tumor-specific responses, despite the argument that the balance between AHR 
and AHRR activity is a major determinant in whether or not pathologic Th17-mediated
autoimmune responses are enabled or protective anti-(self) tumor responses are manifest. 
3. The AHR/AHRR feedback loop
Before considering the contribution of the AHRR to the control of physiological AHR 
functions and its hypothesized role in disease, we will review the current understanding of 
AHRR structure, evolution, expression in normal tissues, and possible roles in embryonic 
development. Additional background on AHRR can be found in other recent reviews [66, 67]. 
3.1. AHRR structure and evolution 
The AHRR was first identified by Fujii-Kuriyama and colleagues [68] as an AHR-related 
cDNA cloned from a mouse intestine cDNA library. When expressed by transient transfection in 
mammalian cells, the murine AHRR inhibited AHR-dependent transactivation of a luciferase 
reporter gene, earning it the designation “AHR repressor” [68]. Similar in vitro repressor activity 



































































negative regulation of AHR signaling is an important and evolutionarily conserved function of 
this protein.
The AHRR shares high amino acid identity with AHR in the N-terminal third of the 
protein (~275 aa) containing the basis helix-lop-helix (bHLH) and Per-ARNT-Sim “A” (PAS-A) 
domains, but the two proteins are highly divergent thereafter. Not surprisingly, considering the 
demonstrated roles of the AHR bHLH and PAS-A domains in DNA binding (basic regions) and 
dimerization to ARNT (HLH and PAS-A domains), the AHRR is capable of interacting with 
ARNT and binding to AHR response elements (AHREs). Consistent with this, it was initially 
hypothesized that the mechanism of AHRR-mediated AHR repression involves competition 
between AHR and AHRR for binding to ARNT and competition of AHR-ARNT and AHRR-
ARNT dimers for binding to AHREs [68]. As described in later sections, the mechanisms 
through which AHRR inhibits AHR activity now appear to be more complicated [72]. Consistent 
with the lack of a recognizable PAS-B domain, which in the AHR functions as the ligand-
binding domain, AHRR does not bind TCDD [69] and appears to act in a ligand-independent 
manner [68]. 
AHRR orthologs have been identified and characterized in several mammalian species 
[68, 71, 73, 74], in an amphibian [75], and in bony fishes [69, 70, 76]. Zebrafish is notable for 
possessing two AHRR paralogs, which, based on phylogenetic analysis and conserved synteny,
appear to be co-orthologs of the mammalian AHRR [76]. An AHRR gene has not been identified 
in any earlier diverging vertebrates or invertebrates, including an invertebrate chordate (Ciona 
intestinalis [77]) or a deuterostome (sea urchin Strongylocentrotus purpuratus [78]. Thus, the 
AHRR is considered a vertebrate-specific member of the AHR subfamily within the PAS gene 



































































structures of the AHRR and AHR genes are highly similar [70, 80]. The AHRR clearly arose from 
a duplication of an ancestral AHR gene; a better understanding of when this occurred in 
vertebrate or chordate evolution awaits the characterization of genomes from cartilaginous and 
jawless fishes.
3.2. AHRR tissue expression, regulation, and role in development 
As shown earlier for the AHR (reviewed in [81]), AHRR mRNA is expressed 
constitutively in a variety of adult tissues, although expression of AHRR appears to be more 
tissue-specific than that of AHR. Although results vary by species and study, the adult tissues 
that consistently express the highest amounts of AHRR mRNA are testis, lung, spleen, heart, and 
kidney [71, 73, 82-84]. In the case of testis, the level of mRNA expression is three times as high 
as the level expressed in the next highest tissues (lung and ovary) and orders of magnitude higher 
than in liver [83]. Notably, in some tissues that express high AHR levels, e.g., liver, basal AHRR
expression is low and AHRR mRNA only becomes easily measurable after induction with 3-MC, 
B[a]P, TCDD or other strong AHR ligands [68, 73, 84, 85]. Interestingly, adult AhRR levels may 
be imprinted during embryogenesis as exposure of murine embryos to TCDD elevates AHRR
mRNA levels in the embryo and in the resulting adult, presumably through epigenetic signaling 
[86]. 
An important consideration in interpreting results concerning tissue-specific expression 
of AHRR mRNA, as with any data on mRNA expression, is that relative mRNA expression may 
not exactly correlate with relative protein levels, and expression of AHRR protein across tissues 
has not yet been assessed in a systematic way. Nevertheless, the data on AHRR mRNA 
expression in adult and embryonic tissues (below) is likely to provide useful information on 



































































Given that activated AHR regulates AHRR transcription [80, 83, 87] it is not surprising 
that four putative AHREs are located in the murine 5’ proximal AHRR promoter located on 
chromosome 13 (Fig. 2) and that at least three of these AHREs are required for AHR-dependent 
transactivation [68, 80]. A highly homologous, putative regulatory region is present at the 5’ end 
of intron 1 of the human AHRR gene located on chromosome 5 [88, 89] and functional AHREs 
also occur in the promoter of fish AHRRs [69]. Overlapping GC sequences enable binding of 
SP1 and SP3 transcription factors to the murine AHRR regulatory region [80]. Importantly, these 
GC boxes are required for optimal constitutive as well as AHR ligand-induced AHRR
transcription in murine or human models [68, 89]. Furthermore, AHRR transcription is induced 
with 12-O-tetradecanoylphorbol-13-acetate, an NF-B activator [68]. An NF-B-binding site is 
located immediately downstream of AHRE #4, overlapping with a GC box (Fig. 2). These 
observations suggest that these highly promiscuous transcription factors regulate AHRR
transcription and, by inference, constitutive AHR activity in the absence of AHR ligands. 
AHRR is expressed in fish and amphibian embryos [70, 75, 76], and in mammalian 
fetuses, where expression appears to be low relative to that in adult tissues [83, 90, 91]. The 
embryo-fetal expression suggests a possible developmental role for the AHRR. Nevertheless, 
AHRR-/- mice are fertile and the offspring appear to develop normally [92], suggesting that 
AHRR may not be required for embryonic development in mice. In zebrafish, however, knock-
down of one of the two AHRR paralogs (AHRRa) using morpholino-modified antisense 
oligonucleotides causes developmental abnormalities like those seen in TCDD-exposed embryos 
[93]. The authors suggest that AHRR may serve to suppress constitutive AHR signaling during 



































































of phenotypes resulting from AHRR knock-out or knock-down in mouse versus fish embryos, 
will require further investigation and clarification. 
In contrast to the still uncertain role of AHRR in regulating constitutive AHR signaling 
during development, there is good evidence for a role for the AHRR in regulating the response to 
AHR agonists in embryos and adults. For example, AHRR-null mice exhibit greater 3-MC-
mediated induction of CYP1A mRNA in skin, stomach, and spleen than wildtype mice, although 
such an enhanced inducibility is not seen in other tissues [92]. Similarly, zebrafish embryos, in 
which expression of AHRRa has been reduced with morpholino oligonucleotides, show an 
increase in TCDD-induced developmental abnormalities. Embryos in which both AHRRa and 
AHRRb have been knocked down display enhanced induction of CYP1A by TCDD at 72 hours 
post fertilization [93]. The role of the AHRR in regulating responsiveness to AHR agonists in 
utero is further suggested by the ability of these compounds to induce high levels of AHRR
mRNA in fish or murine embryos, the latter occurring via placental transfer [70, 76, 86, 91].
As a consequence of emerging studies implicating an inducible AHR/AHRR feedback 
loop in embryos as well as in adult tissues, there has been great interest in evaluating a possible 
role for the AHRR in governing species-, population- or strain-specific differences in sensitivity 
to dioxins and related compounds. For example, elevated AHRR expression has been considered 
as a potential mechanism for the PCB resistance that has evolved in fish inhabiting highly 
contaminated environments. However, studies in three different resistant populations and two 
different species have consistently shown no elevation in constitutive expression of AHRR
transcripts in the resistant fish [69, 76]. In contrast, in all three studies, the AHRR resembled 
CYP1A in being refractory to induction by exposure to AHR agonists in the laboratory. The 



































































hypothesized; however, the developmental pattern of AHRR expression in Xenopus laevis is not 
consistent with such a role [75]. AHRR also has been evaluated as a contributing factor in the 
AHR-dependent dioxin resistance of the Han/Wistar (Kuopio) rat strain. However, the basal 
expression and inducibility of AHRR mRNA does not differ between dioxin-sensitive and dioxin-
resistant strains [73].
3.3. The central AhR/AHRR feedback paradigm-Is it always valid?
The context in which the AHRR was first and most frequently described involves its 
induction by exogenous AHR ligands such as TCDD [69], 3-methylcholanthrene (3-MC)[80], or 
benzo[a]pyrene (B[a]P)[84]. These studies generally point to a straightforward feedback loop 
wherein AHR-induced AHRR suppresses AHR activity. Accordingly, AHRR mRNA levels
generally increase after AHR activation with TCDD or PAH, and CYP1A1 induction with 
xenobiotics appears to be repressed in primary cells and some cell lines with high basal AHRR
levels [82, 94]. For example, HeLa cells express very high basal AHRR mRNA levels and are
relatively resistant to CYP1A1 induction with TCDD or 3-MC [82]. Reduction of AHRR 
expression using siRNA restores CYP1A1 inducibility, demonstrating the ability of high basal 
AHRR levels to constitutively repress AHR activity [89]. Some, but not all (see below) studies 
evaluating AHR activated in the absence of xenobiotics (“constitutively active AHR”), suggest 
that this model applies to “physiologically” activated AHR as well. For example, mammalian 
lung constitutively expresses relatively high levels of both AHR and AHRR, a result consistent 
with regulation of basal AHRR levels by endogenously activated AHR [83]. Furthermore, AHRR
mRNA is decreased in brain and heart from naïve AHR-/- mice [84] and basal CYP1A1 levels are 



































































basal AHRR levels are regulated, at least sometimes, by constitutive AHR activity, which in turn 
is limited by the AHRR.
However, as with many aspects of AHR-target gene interactions, the outcome of AHR-
AHRR interactions is likely to be more complex than suggested by a simple AHR-induced, 
AHRR-mediated feedback model. That is, the ability of the AHR to transactivate the AHRR gene, 
and the ability of AHRR to repress AHR activity, at least as defined by CYP1 induction, is likely 
to be tissue-, cell-, and context-specific. A hint of this complexity is provided by the observation 
that B[a]P induces significant CYP1A1 transcription in the murine kidney (reaching 
approximately half of the CYP1A1 induced in the liver), but does not induce detectable levels of 
AHRR mRNA [84], a result demonstrating that ligand-activated AHR may not be able to 
transactivate AHRR in all tissues. Similarly, some cell lines derived from testis, lung, kidney, or
bladder express low or moderate basal AHRR levels that are not increased following AHR ligand 
exposure [82].
The feedback component of the model also may be tissue specific. The testis 
notwithstanding, the overall tissue expression of the AHRR and the ability of AHR ligands to 
induce CYP1A1 mRNA are not always  inversely correlated [84]. Thus, while basal AHRR levels 
in the murine heart are approximately 5 fold higher than in the liver, CYP1A1 inducibility is 
comparable in both organs [84]. Similarly, TCDD-induced AHRR and CYP1A1 transcription do 
not inversely correlate in rat kidney, spleen, heart [73] or hypothalamus [85]. These data suggest 
that AHRR levels alone do not necessarily dictate the magnitude of AHR responses and that 
AHRR activity may be modulated in a tissue-specific fashion. An important caveat here is that 



































































between AHRR protein levels and AHR ligand-mediated CYP1A1 inducibility still requires 
elucidation. 
4. AHRR polymorphisms and disorders of human reproduction
One of the most intriguing and controversial hypothesis to arise concerning the 
physiological activity of AHRR concerns its possible role in human reproduction. Because the 
constitutively active and xenobiotic activated AHR has long been linked to reproductive 
physiology [51, 95-98], an involvement of AHRR in reproduction has been viewed as plausible, 
although a review of the literature demonstrates some significant inconsistencies. Studies to date 
have focused on the Pro185Ala single-nucleotide polymorphism first reported by Watanabe et al. 
[87]. In this initial study, no link was found between AHRR genotype and the occurrence of 
uterine endometriosis in a Japanese population. However, two subsequent studies did find such 
an association. Japanese women with at least one copy of the Ala185 allele were reported to be at 
increased risk for both the occurrence and increased severity of endometriosis [99]. Similarly, in 
a study of Korean women, the frequency of the Ala185 allele was slightly but significantly 
increased in women with advanced stage endometriosis as compared to women without the 
disease [100]. 
The same AHRR polymorphism also has been linked to male reproductive abnormalities. 
Two reports [90, 101] have shown an association of the Pro185 allele and Pro/Pro genotype with 
the incidence of micropenis, a condition characterized by undermasculinized external genitalia in 
the absence of other abnormalities. Fujita et al. [90] suggested that the Pro185 allele might be a 
hypomorphic allele with a weaker inhibitory effect on AHR. The Pro/Pro genotype also has been 
associated with male infertility (azoospermia or severe oligospermia) in a Japanese population 



































































risk for male infertility [103]. The Ala185 allele also contributed to an association between 
organochlorine exposure and the X:Y ratio of sperm in a group of Swedish fishermen [104].
The frequent association between AHRR genotype and increased risk for male and female 
reproductive abnormalities is striking. However, the lack of consistency in the specific AHRR 
variant associated with the abnormal condition (Ala or Pro) raises questions about the underlying 
explanation for these observations. There are no published studies evaluating the functional 
characteristics of the two variant AHRR proteins. However, recent work suggests that both 
variants exhibit similar activity as repressors of AHR signaling [105, 106]. If differences in the 
function or expression of the variant AHRR alleles are not identified, the epidemiological results 
might be explained not by the AHRR itself but by polymorphisms in a nearby gene that is in 
linkage disequilibrium with AHRR.  Thus, despite the intriguing results emerging from these 
epidemiological studies, the link between AHRR and reproductive disorders remains to be 
elucidated.
5. AHRR and cancer
Another remarkable aspect of AHR biology, and by inference AHRR biology, is the 
apparent contribution of the AHR to malignancy. The earliest AHR research demonstrated that 
the AHR is required for optimal CYP1A1 or CYP1B1 induction, production of mutagenic 
metabolites, and tumor initiation [107]. Since then, the role of the AHR in both genetic and 
epigenetic regulation in a variety of tumors has been well documented. Indeed, it is now 
generally accepted that both environmental chemical-activated [56] and constitutively active 
AHR [4] contribute to tumorigenesis and aberrant cell behavior. 
Despite these important observations, relatively little is known of AHRR expression and 



































































critical role for the AHRR in cancer. For example, we have noted increased expression of AHRR
mRNA in non-metastatic murine mammary tumors induced by oral gavage with DMBA, relative 
to AHRR levels in normal mammary glands. In human mammary tumor cell lines, AHRR knock-
down with siRNA reduces AHR activity (data not shown), confirming the assumption that the 
AHRR constitutively represses AHR activity in tumors. Interestingly, murine breast tumors 
induced with DMBA generally express extremely high AHR levels [2], although the AHR
protein and AHRR mRNA levels do not necessarily correlate in any given tumor. Indeed, 
individual tumors with high AHR levels tend to express low basal AHRR levels, suggesting the 
intriguing possibility that the AHR actually may suppress AHRR transcription and thereby 
maximize AHR activity. 
The ability of the AHRR to regulate important tumor cell functions was exemplified by 
the demonstration that stable AHRR transfection decreases E2F, cyclin E1, and PCNA and slows 
the growth of ER positive MCF-7 cells [60]. Interestingly, this growth inhibition may be 
mediated by direct interaction of the AHRR with ER [108]. (This and other potential AHR-
independent AHRR effects are discussed later in this article). AHR and AHRR control of 
mammary tumor cell growth also extends to ER negative cells, as we have demonstrated that 
ectopic AHRR expression slows the growth of immortalized MCF-10F mammary epithelial cells 
expressing constitutively active AHR but no ER [4].
Regardless of the mechanism through which the AHRR affects mammary tumor cell 
growth, these studies suggest the intriguing possibility that the AHRR is essentially a tumor 
suppressor gene. Indeed, this thesis has recently been put forth by Zudaire et al [55]. These
investigators noted that the short arm of human chromosome 5, the region containing the AHRR



































































ovarian, bladder, esophageal and lung cancers. Consequently, this region is thought to encode an 
important tumor suppressor gene(s). The finding that the AHRR promoter is hypermethylated in 
a variety of tumor cell lines and primary tumors from multiple organs, leading to decreased 
levels of AHRR mRNA levels as compared with corresponding “normal” tissue, suggests that the 
AHRR may be one such tumor suppressor [55]. A correlation between AHRR promoter 
hypermethylation and tumor grade in cervical and esophageal malignancies and a modest 
decrease in AHRR mRNA in pre-cancerous colon polyps as compared with a more profound 
decrease in primary invasive colon carcinomas implies a continuous process of AHRR down-
regulation and AHR activity up-regulation during malignant transformation. Importantly, it was 
shown that AHRR down-regulation with siRNA increases the growth and invasiveness of lung 
carcinoma cell lines and enables non-malignant MCF-10A cells to grow in soft agar [55]. These 
important studies highlight the importance of both the AHR and the AHRR in tumorigenesis and 
further underscore the relevance of a balance between AHR and AHRR in physiologic processes 
occurring in the apparent absence of environmental AHR ligands.
These results bring up yet another intriguing possibility. The association between AHRR 
silencing by hypermethylation in situ and increased tumorigenicity suggests that progressing 
tumors would display enhanced growth resulting from AHRR down-regulation, regardless of the 
mechanism. We and many others have shown that AHR behavior is tissue and stimulus specific. 
For example, while TCDD-activated AHR induces CYP1A1 and CYP1B1 [20], it represses genes 
encoding hsp27 [48] and cathepsin D [109] in mammary tumor cell lines. Furthermore, in cells 
in which TCDD induces both CYP1A1 and CYP1B1, constitutively active AHR preferentially 
up-regulates CYP1B1, but does little or nothing to transactivate CYP1A1 [3] and actually 



































































target genes. Therefore, it seems plausible that, under some circumstances where AHR activity 
enhances cell growth or survival, the AHR will be found to suppress AHRR transcription, thereby 
relieving the AHR of a negative feedback loop. Indeed, recent results showing increased AHRR
expression in spleen and thymus of AHR-/- mice [84] are consistent with this  hypothesis. 
6. Mechanisms of AHRR action
An understanding of the molecular mechanisms by which the AHRR inhibits AHR 
signaling is important for elucidating the regulatory interactions of these two proteins in the 
context of cell growth. Similarly, understanding the specificity of the AHRR, i.e. whether it also 
controls other signaling pathways, also is essential. Both of these aspects of AHRR function, its 
mechanism of repression and specificity with respect to AHR, are often assumed to be well 
understood. However, this is not yet the case; key questions about AHRR function remain to be 
resolved, as described below.
6.1 Molecular mechanisms of repression
There is no doubt that the AHRR is a transcriptional repressor of AHR. This has been 
demonstrated repeatedly with reporter constructs in transfected cells [68-70, 72, 110] and with 
endogenous target genes such as CYP1A and c-myc [20, 55, 68, 89]. Two additional features of 
AHRR’s mechanism that are not disputed include its ligand-independence and constitutive 
nuclear localization. For example, the association of AHRR with ARNT in co-
immunoprecipitation experiments did not require, and was not enhanced by addition of an AHR 
ligand [68]. Karchner et al. [69] directly evaluated the ability of mammalian and fish AHRRs to 
bind [3H]TCDD, and found no evidence of specific binding like that seen for AHR. Both of these 
results are consistent with the lack of conservation between AHRR and AHR in the PAS-B 



































































that AHRR-GFP fusion proteins, and presumably native AHRRs, are localized primarily to the 
nucleus of transfected cells [68, 72, 111]. Kanno et al. [111] showed that AHRR contains both 
nuclear localization and nuclear export sequences, and that AHRR undergoes nucleocytoplasmic 
shuttling, with equilibrium favoring nuclear localization. They also suggested a role for ARNT in 
AHRR nuclear transport. Together, these studies reveal that the AHRR is a ligand-independent, 
nuclear repressor of (AHR) transcription.
The exact molecular mechanism by which the AHRR represses transcription is more 
uncertain. The initial report identifying the AHRR as a repressor of AHR transactivation 
proposed two mechanisms of repression: competition with AHR for binding to ARNT and 
competition between AHR-ARNT and AHRR-ARNT complexes for binding to DNA [68]. The 
authors presented data and described additional, unpublished results in support of these proposed 
mechanisms.  For example, Mimura et al. [68] used co-immunoprecipitation studies to 
demonstrate that the AHRR associates with ARNT, a requirement for both putatitive 
mechanisms. In addition, these authors showed that AHRR-ARNT complexes bind to AHR 
response elements (AHREs; also called DREs or XREs), making it plausible that competition 
between AHR-ARNT and AHRR-ARNT complexes is involved in the mechanism of repression. 
While the hypothesized mechanisms of AHRR-mediated AHR suppression are appealing 
in their simplicity, closer examination reveals that the mechanism of repression is likely to be 
more complex. Recently, we performed experiments to directly test both hypothesized 
mechanisms of repression [72, 112]. In these studies, ARNT overexpression had no effect on 
AHRR-mediated repression of AHR, demonstrating that competition for ARNT is not the 
primary mechanism of repression. In addition, through the use of an AHRR point mutant 



































































abolished, we showed that AHRE binding was not required for repression, although a slight 
decrease in repressive potency of this mutant suggested that AHRE binding may contribute to 
AHR repression. The results obtained with this point mutant were similar to unpublished results 
reported earlier involving use of an AHRR lacking the basic region [68], although in that case 
the ability of the mutant to still localize to the nucleus was not confirmed. In a key experiment, 
we showed that DNA-binding mutant AHRR-Y9F, even in the presence of excess ARNT, was 
still a potent repressor of AHR [72]. Thus, when both hypothesized mechanisms were precluded 
through experimental manipulations, the ability to repress was maintained, indicating that there 
may be an additional mechanism of repression. These results [72] suggest that this additional 
mechanism might involve transrepression (repression through protein-protein interactions, but 
independent of direct DNA binding by the repressor). A repression mechanism that is 
independent of DNA binding is reminiscent of recent findings showing that the AHR can act as a 
coactivator to activate transcription without binding to DNA [17, 113]. The transrepression 
hypothesis, although consistent with the published results [72], remains to be verified through 
identification of the specific protein-protein interactions that are involved. Nevertheless, there 
appear to be at least two mechanisms by which AHRR can repress AHR-dependent transcription 
(summarized in Fig. 3).
Two groups have attempted to localize the regions of the AHRR protein that are 
important for repression. We constructed two deletion mutants of a zebrafish AHRR, 
AHRR1270-550 (truncated after the portion of the AHRR PAS domain that is conserved in 
AHRs and AHRRs) and AHRR1189-550 (lacking most of the PAS domain but retaining the 
PAS-A repeat) [72]. In transient transfection assays, AHRR1270-550 was as effective as the 



































































AHRR1189-550 was still fully active as a repressor, but required higher amounts of transfected 
DNA [72]. We concluded that the C-terminal half of AHRR is not required for repressor activity.
In what at first appears to be contradictory results, Oshima et al. [110] found that the C-
terminal segment of AHRR (aa 555-701 of mouse AHRR) contains a repressor domain. This 
result was obtained with an engineered system involving chimeric proteins containing the DNA 
binding domain of the yeast Gal4 protein fused to various parts of the AHRR, with repressor 
activity measured as the ability to inhibit expression of a constitutively active luciferase reporter 
gene driven by the TK promoter and Gal4 binding sites. Thus, the assay involves binding of the 
chimeric proteins to Gal4 binding sites on the reporter vector, and therefore measures repression 
that is dependent on DNA binding of the AHRR protein (albeit to a heterologous sequence). In 
support of the repressive role of the AHRR C-terminal portion, Oshima et al. identified 
ANKRA2 as a possible co-repressor that interacts with aa 342-701 of AHRR to recruit histone 
de-acetylases HDAC4 and HDAC5. 
Although the experiments of Evans et al. [72, 112] and Oshima et al. [110]  identified 
different ends of the protein as being involved in repression and thus at first seem contradictory, 
the results may in fact not be in conflict. In the latter study, the role of ANKRA2 in repression of 
CYP1A expression was assessed by blocking ANKRA2 expression with siRNA in mouse embryo 
fibroblast cells. Only a small effect on basal CYP1A expression (2-fold) was seen, and there was 
no effect of ANKRA2 knock-down on 3-MC-induced CYP1A expression. In contrast, blocking 
AHRR expression with siRNA affected both basal expression of CYP1A (5-fold increase) and 3-
MC-induced expression (2-fold increase). The authors concluded that AHRR can act by an 
ANKRA2-independent mechanism of repression. The results of Evans et al. [72, 112] would 



































































domain-containing part of the protein. This conclusion is consistent with the evolutionary 
conservation of AHRR function in vertebrates, despite the low degree of sequence conservation 
in the C-terminal half of the protein [70]. 
6.2 AHRR specificity
The initially proposed mechanisms responsible for AHRR-mediated AHR suppression 
involving competition for ARNT and AHREs would predict that AHRR is a specific repressor of 
AHR, with possible effects (although likely reduced) on other ARNT-dependent bHLH-PAS 
proteins such as HIF or SIM. In contrast, a transrepression mechanism independent of AHRE 
binding allows for the potential of AHRR to have broader specificity; just how broad depends on 
the exact mechanism by which the transrepression occurs. Thus, the question of AHRR 
specificity is intimately tied to its mechanism of action. Indeed, the very name “AHR repressor” 
creates a mindset that may prevent us from considering other possible targets of this protein. 
Hints of a broader range of AHRR targets were contained in the original report on the 
existence of an AHR repressor [68]. In that study, AHRR repressed the ability of a Gal4-ARNT 
chimeric protein to transactivate a reporter construct driven by Gal4 binding sites. In addition, 
these authors reported (but did not show) that AHRR “…moderately inhibited transactivation by 
the HIF-1/Arnt heterodimer” [68]. More recently, Karchner et al. [106] showed that AHRR 
repressed HIF-1 activation of an HRE-luciferase reporter construct. Consistent with this result 
and the known role of HIF proteins in angiogenesis, Zudaire et al. [55]  showed that AHRR 
expression in tumor cells was inversely correlated with their angiogenic potential. 
One important question is whether AHRR can repress proteins other than those in the 



































































nuclear receptors ER or PXR (pregnane-X-receptor) to activate transcription through their 
respective enhancer elements. The results with ER are in contrast to another recent report 
showing that AHRR can repress ER-mediated transactivation of reporter genes and endogenous 
target genes, and that the AHRR interacts directly with ER at multiple sites on the ER protein 
[108]. This difference remains to be resolved. It seems clear, however, that AHRR is capable of 
repressing more than just the AHR, and that its targets may not be limited to bHLH-PAS proteins. 
Identification of all such targets of AHRR repression will help elucidate the role of this protein in 
potentially regulating many biologic functions.
7. Conclusions and future directions
This article and others presented in this Biochemical Pharmacology issue underscore the 
importance of the AHR as an inducible signal-transducing transcription factor in many biologic 
contexts. While a nearly exponential increase in the number of studies on the AHR has occurred 
over the last few years, progress on the analysis of its repressor has been considerably more 
modest. (At the time of this writing, a search of PubMed using the words “aryl” or “aromatic” + 
“hydrocarbon” + “receptor” yielded 5,085 hits while a search using “aryl” or “aromatic” + 
“hydrocarbon” + “receptor”  + “repressor” yielded 137 hits). If it is conceded that the AHR is an 
important intracellular signal transducer under “normal” physiological conditions, after exposure 
to xenobiotic agonists, or during tumor progression, then it should be concluded that whatever 
regulates the AHR is of equal importance. The analysis of AHR co-activators and co-repressors 
[15-17] is one important step in that direction. Elucidation of AHRR expression and function is 
another. 
Studies summarized here suggest that, like the AHR and at least in part because of the 



































































embryogenesis. A generally increased level of AHRR expression in adult as compared with 
embryonic tissues [83], and an asymmetric tissue-specific expression of AHRR mRNA (e.g., 3 
times to greater than 30 times higher AHRR levels in testis than any other organ)[83], suggest an 
important and tissue-specific contribution to adult organ function as well. Additional studies 
suggest important roles for the AHRR in disease including but not limited to cancer.
The classical analysis of AHR function by stimulation with well-characterized 
xenobiotics has led to a central paradigm in which xenobiotic-mediated AHR activation results 
in AHR-mediated transcriptional up-regulation of AHRR, the protein product of which feeds 
back to limit AHR activity. Some studies, for example with brain and heart from AHR-/- mice, 
which exhibit decreased AHRR expression, suggest a similar feedback loop when the AHR is 
activated in situ either through an endogenous ligand or through some as yet undefined ligand-
independent mechanism. However, alternative consequences must be considered. For example, 
an increase in AHRR transcript levels in spleens and thymi of AHR-/- mice [84] and the inverse 
relationship between AHR expression (high) and AHRR transcripts (low) in primary murine 
mammary tumors [2](data not shown) suggest the intriguing possibility that the AHR, under 
some circumstances, may actually repress transcription of its own repressor, thereby maximizing 
AHR activity. If it is accepted that, at least under some [1, 2, 4-6, 21] though perhaps not all [29]
circumstances, increased AHR activity contributes to malignancy, then this alternative pathway 
of AHR-mediated repression of AHRR expression would be consistent with the view of the 
AHRR as a tumor suppressor protein, as recently proposed by Zudaire et al  [55]. Indeed, it 
would provide a second epigenetic mechanism, in addition to AHRR hypermethylation [55], 



































































Finally, plausible mechanisms through which the AHRR inhibits AHR activity, i.e., 
competitive binding to ARNT, competitive binding of ARNT/AHRR dimers to AHREs [68, 114], 
and recruitment of co-repressors [110], have been proposed and supported by some experimental 
data. However, recent studies demonstrating that AHRR mutants incapable of binding AHREs 
still suppress AHR activity, even in the presence of excess ARNT [72, 106, 112], suggest that, as 
is often the case, mechanisms are more complex than initially appreciated. Furthermore, studies 
demonstrating AHRR-mediated inhibition of HIF-1 signaling [68, 106] and physical association 
of the AHRR with the ER [108] encourage caution in ascribing all AHRR activity to its 
propensity to block AHR activity. Future studies on this very important transcriptional regulator 
must consider these putative “off-target” effects.
Clearly, many important questions concerning the function of AHRR remain to be 
answered. In what cells and developmental stages does AHRR limit the activity of constitutively 
active or xenobiotic-activated AHR? Which other transcription factors are targets for repression 
by AHRR? What are the exact molecular mechanisms of repression and do they differ for 
different transcription factors and target genes? What is the precise role of AHRR and its 
polymorphic variants in reproductive disease and cancer?  Answers to these and many other 
questions about the AHRR will enrich our understanding of AHR biology and quite possibly the 
biology of other signaling pathways as well.
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Figure 1. Silencing of AHR expression with AHR-specific siRNA slows human B cell 
growth 
(A) Purified human B cells from a minimum of 5 human donors were activated by 
culturing on CD40 ligand (CD40L)-transfected L cells plus rIL-4 for 1 week. CD40L-activated B 
cells were transfected with AHR-specific siRNA or, as a negative control, lamin A/C-specific 
siRNA. Cells were harvested after 24 hours, protein extracted and assayed for AHR levels by 
immunoblotting. Blots were re-probed with ß-actin-specific antibodies to control for protein 
loading. Data from a representative experiment (5 total) are shown. (B) B cells activated with 
CD40 ligand as in (A) were transfected with AHR or Lamin A/C siRNA. Twenty four hours later, 
cells were restimulated with CD40L and rIL-4, 3H-thymidine added, and 3H-thymidine 
incorporation assayed 18 hours later. The means of the triplicate counts were averaged for each 
experiment. Data are presented as mean ± SE from 4 donors, cells from which were transfected 
in separate experiments. An asterisk (*) indicates a significant decrease in 3H-thymidine uptake 
of AHR-specific siRNA-transfected cells as compared with lamin-specific siRNA-transfected 
cells (p< 0.05; paired t-test).
Figure 2: AHR, NF-B, and SP-1/3 binding sites in AHRR regulatory regions
The murine AHRR proximal promoter on chromosome 13 contains 4 AHREs (closed 
ovals), 2 overlapping and 1 additional GC boxes (open rectangles), and 1 NF-B binding site 
which overlaps with one of the GC boxes (closed diamond). Each of these sites has been 



































































A highly homologous regulatory sequence is located on the 5’ end of the human AHRR gene on 
chromosome 5.
Figure 3: Mechanisms of repression by AHRR 
Two hypothesized mechanisms by which AHRR can repress transactivation by AHR.
The AHR illustrated in this figure represents AHR that is either constitutively active or has been 
activated by exogenous ligand (not shown). One mechanism of repression involves competition 
with AHR for binding to AHR response elements (AHREs) in the promoters of AHR target 
genes, as originally proposed [68]. The AHRE-bound AHRR may recruit co-repressors such as 
ANKRA2 and histone deacetylases [110]. This mechanism is likely to require ARNT as part of 
an AHRR-ARNT complex, but does not involve competition for dimerization with ARNT [72, 
106, 112]. A second hypothesized mechanism is independent of competition for ARNT or 
AHREs, and may involve transrepression [72, 106, 112]. The hypothesized transrepression 
mechanism is illustrated using an AHRR-ARNT dimer, but whether this mechanism requires 
ARNT or occurs in an ARNT-independent manner (i.e. by the AHRR alone or as complex with 
other proteins) is not yet known. The transrepression mechanism could be involved in the AHR-
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